UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): January 23, 2017

 

  PixarBio Corporation

(Name of Small Business Issuer in its Charter)

 

Delaware

47-1945113

(State or Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification No.)

 

200 Boston Avenue, Suite 1875

Medford, MA 02155

(Address of principal executive offices)

 

(617) 803-8838

(Telephone Number of Principal Executive Offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 
 

Item 1.01 Entry into a Material Definitive Agreement

 

On January 23, 2017, PixarBio Corporation, a Delaware corporation (the “Company”), held an initial closing with an accredited investor, pursuant to which the Company sold an aggregate of 133,334 newly issued shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”) at a purchase price of $2.25 per share (the “Private Placement”). Included with each share is a seven year warrant to purchase one share of Common Stock at $4.50.

 

Item 3.02 Unregistered Sales of Equity Securities

 

The information set forth in Item 1.01 of this Current Report on Form 8-K concerning the sale of shares of Common Stock to the Purchasers is incorporated herein by reference. The shares of Common Stock issued and sold as described in Item 1.01 were offered and sold by the Company in reliance upon an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D promulgated thereunder.

 

 

 2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PixarBio Corporation

(the Company)

 

Dated: January 27, 2017

By: 

/s/ Francis M. Reynolds

 

Francis M. Reynolds

 

Title: Chief Executive Officer

 

 

 3